Suvarna Garge

Cefdinir

Updated on
Share on FacebookTweet on TwitterShare on LinkedIn
Trade names  Cefzon, Omnicef
MedlinePlus  a698001
ATC code  J01DD15 (WHO)
AHFS/Drugs.com  Monograph
Routes of administration  Oral
Cefdinir
Pregnancy category  US: B (No risk in non-human studies)

Cefdinir is a third-generation oral cephalosporin antibiotic sold under the brand names Cefzon and Omnicef.

Contents

As of 2008, cefdinir, as Omnicef, was the highest-selling cephalosporin antibiotic in the United States, with more than US$585 million in retail sales of its generic versions alone. Cephalosporin is structurally similar to cefixime.

It was discovered by Fujisawa Pharmaceutical Co., Ltd. (now Astellas) and introduced in 1991 under the brand name Cefzon. Warner-Lambert licensed this cephalosporin for marketing in US from Fujisawa. Abbott obtained U.S. marketing rights to Omnicef (cefdinir) in December 1998 through an agreement with Warner-Lambert Company. It was approved by FDA on Dec 4, 1997. It is available in US as Omnicef by Abbott Laboratories and in India as Cednir by Abbott, Kefnir by Glenmark, Cefdair by Xalra Pharma and Cefdiel by Ranbaxy.

Indications

Therapeutic uses of cefdinir include otitis media, soft tissue infections, and respiratory tract infections, including sinusitis, strep throat (note: no documented resistance of Group A Streptococcus to penicillin has ever been reported, and penicillin or amoxicillin is preferred except in penicillin allergic patients), community-acquired pneumonia, and acute exacerbations of bronchitis.

Susceptible organisms

Cefdinir is a bacteriocidal antibiotic of the cephalosporin class of antibiotics. It can be used to treat infections caused by several Gram-negative and Gram-positive bacteria.

Spectrum of bacterial susceptibility and resistance

Cefdinir is a broad-spectrum antibiotic and has been used to treat infections of the respiratory tract including pneumonia, sinusitis, and bronchitis. The following represents MIC susceptibility data for a few medically significant microorganisms.

  • Haemophilus influenzae: 0.05 - 4 μg/ml
  • Streptococcus pneumoniae: 0.006 - 64 μg/ml
  • Streptococcus pyogenes: ≤0.004 - 2 μg/ml
  • Side effects

    Side effects include diarrhea, vaginal infections or inflammation, nausea, headache, and abdominal pain."

    It is also one of the medications that can cause toxic epidermal necrolysis or Stevens-Johnson Syndrome.

    Available forms

    Cefdinir is administered orally. It is available as capsules and a suspension. Dosage, schedule, and duration of therapy varies according to the type of infection.

    "Blood" in the stool

    The pediatric version of cefdinir can bind to iron in the digestive tract; in rare cases, this causes a rust or red discoloration of the stool. Blood typically appears dark brown or black in stool, and testing may confirm which is present. If the reddish stool is accompanied by abdominal pain, weight loss, diarrhea, etc., a Clostridium difficile infection caused by the antibiotic could be signified.

    Synthesis

    Acylation of the primary amine 1 with 4-bromo-3-oxobutanoyl bromide (2) leads to the amide (3). The active methylene group in that product is then nitrosated with sodium nitrite; the initial product spontaneously tautomerizes to afford the oxime (4). The bromoketone array in that intermediate constitutes a classical starting function for construction of thiazoles. Reaction of 4 with thiourea thus leads to formation of an aminothiazole moiety. Thus there is obtained the antibiotic cefdinir (5).

    References

    Cefdinir Wikipedia


    Similar Topics
    Yorokobi mo kanashimi mo ikutoshitsuki
    Matías Cahais
    Ada den Haan
    Topics